Articles for author: Russ Cohen

Russ Cohen

Most Popular

Stock Market News: NRIX and APLD

Diverging Fortunes in the Market Stock futures showed a mix of trends in the premarket hours on Friday, with investors eagerly anticipating earnings reports from major banks. Amidst this dynamic landscape, some stocks stood out for their significant movements. The Winners and the Losers While some stocks surged, others experienced significant downturns, exemplifying the unpredictable ...

Russ Cohen

Most Popular

The Momentum Trio: A Look at Top Stocks to Consider Buying

MakeMyTrip Limited: Riding the Wave MakeMyTrip Limited (MMYT), the online travel company, has seen a remarkable upsurge in its Zacks Rank, currently standing at #1. What’s even more impressive is the 2.1% surge in the Zacks Consensus Estimate for its upcoming year earnings over the past 60 days. With a momentum score of B, MakeMyTrip’s ...

Russ Cohen

Most Popular

Unveiling Promising Stocks Under $7 Unveiling Promising Stocks Under $7

Imagine traversing a bustling marketplace, your eyes catching a glint of gold amidst a sea of lesser values. Stocks under $7, although capricious, hold the promise of outsized returns for those bold enough to weather the storm. SoundHound (SOUN) Source: rafapress / Shutterstock.com SoundHound (NASDAQ:SOUN) stands as a luminary in the realm of artificial intelligence ...

Russ Cohen

Most Popular

Unveiling Potential: 6 AI Stocks Analysts Predict to Surge Unveiling Potential: 6 AI Stocks Analysts Predict to Surge

Exploring Overlooked Gems in the AI Market The impact of artificial intelligence (AI) on the market has been nothing short of a juggernaut in recent years. Driving significant market gains and poised to continue its ascent, the AI megatrend is making waves across various industries. Projections indicate that the AI market could swell to a ...

Russ Cohen

Most Popular

The Evolution of Pharmaceutical Giants in the Face of Adversity

Turning to Cancer and Heart Disease in the Crisis The pharmaceutical titans like Bristol Myers Squibb, Merck & Co Inc, Pfizer Inc, and Johnson & Johnson are standing at the edge of a cliff – a patent cliff. With billions of dollars in revenue at stake, the expiration of patents for their flagship products threatens ...